NASDAQ:WVE

Wave Life Sciences Stock News

Healthcare > Biotechnology

Buy WVE

*Your capital is at risk

$5.76

+0.0700 (+1.23%)

At Close: Jun 03, 2026

Wave Life Sciences' stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial

01:41pm, Tuesday, 24'th Sep 2024

Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.

Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

07:30am, Tuesday, 24'th Sep 2024

Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two iso

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

10:49am, Friday, 20'th Sep 2024

The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small pharmaceutical companies like Wave Life Sciences NASDAQ: WVE, whose shares rose

Wave Life Sciences Ltd. (WVE) Q2 2024 Earnings Call Transcript

10:27am, Saturday, 10'th Aug 2024

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - P

Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates

09:46am, Thursday, 08'th Aug 2024

Wave Life Sciences (WVE) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.20 per share a year ago.

Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

07:30am, Thursday, 08'th Aug 2024

Successful clinical translation of Wave's RNA medicines platform in HD patients with WVE-003 provides further validation of Wave's proprietary platform with PN and stereochemistry; opt-in package for

Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

08:30am, Thursday, 01'st Aug 2024

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform

What's Going On With Wave Life Sciences Stock On Tuesday?

09:37am, Tuesday, 25'th Jun 2024

Wave Life Sciences Ltd WVE announced results from its Phase 1b/2a SELECT-HD trial of WVE-003, which is being developed as a potential disease-modifying therapeutic for Huntington's disease (HD).

Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing

08:30am, Wednesday, 12'th Jun 2024

Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave's INHBE program as a best-in-class approach for obesity

Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)

08:30am, Tuesday, 30'th Apr 2024

Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024 Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by